Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D.
Rhea-AI Summary
Seer (Nasdaq: SEER) confirmed receipt of two further revised, unsolicited, non-binding acquisition proposals for all outstanding shares of its Class A common stock. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right.
On July 29, 2026, Omid Farokhzad, M.D., Seer’s Chair and CEO, submitted a revised proposal for $2.45 per share in cash plus two separate contingent value rights. According to Seer, its previously constituted Special Committee, with advisors, will review both proposals and other alternatives. No stockholder action is required at this time.
Positive
- Competing cash bids at $2.55 and $2.45 per Class A share, both covering all outstanding shares
- Both proposals include contingent value rights, potentially providing additional consideration beyond the stated cash price per share
Negative
- Both acquisition proposals are unsolicited and non-binding, so there is no assured transaction or timeline for Seer stockholders
- Seer states that no stockholder action is required yet, indicating potential near-term uncertainty before any clear outcome emerges
News Explained
The company says the full text of Dr. Farokhzad’s revised, still non-binding proposal will be included in a Form 8-K, the filing used to report specified material events; that filing is the identified source for additional proposal detail.
News Market Reaction – SEER
In the Jul 31 session, SEER gained 7.77%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.6% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 28 | Revised acquisition proposal | Positive | +8.6% | Radoff-JEC Group submitted a further improved proposal to acquire Seer. |
| Jul 20 | Acquisition proposal rejection | Negative | -6.0% | Special Committee unanimously rejected the CEO's unsolicited acquisition proposal. |
| Jul 06 | Acquisition proposal response | Positive | +35.2% | Radoff-JEC Group responded to the CEO's acquisition proposal. |
| Jul 02 | Acquisition proposal | Positive | +35.2% | Seer announced receipt of the CEO's unsolicited acquisition proposal. |
| May 27 | Premium proposal review | Positive | +2.1% | Radoff-JEC Group urged Seer to reevaluate its premium acquisition proposal. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The five acquisition-tagged events each showed price reactions directionally consistent with the event sentiment.
Key Terms
contingent value right financial
special committee regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
No Stockholder Action Required at This Time
REDWOOD CITY, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that on July 28, 2026, it received a further revised, unsolicited, non-binding acquisition proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”) to acquire all of the outstanding shares of Seer’s Class A common stock for
On July 29, 2026, Seer received a revised, unsolicited, non-binding acquisition proposal from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for
The previously constituted Special Committee of Seer’s Board of Directors, in consultation with its advisors, will carefully review and consider both proposals, as well as other alternatives available to Seer, and determine the course of action that it believes is in the best interests of Seer and all Seer stockholders.
No stockholder action is required at this time.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer's Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
For more information, please email us at pr@seer.bio.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this communication. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the actions of the Special Committee. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
pr@seer.bio
Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449
